Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins
ConclusionsFurther LDL-C reductions through the addition of BA+EZE FDC to maximally tolerated statins are predicted to reduce major adverse cardiovascular events compared with the addition of EZE. Benefits are potentially greater among those with higher starting LDL-C.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Heart | Nutrition | Statin Therapy | Vytorin | Zetia